

In re Appln. No. 09/429,331

#### REMARKS

1. At the time the February 20, 2001, response was prepared, counsel's file copy of the specification was missing page 237. Hence, the sequences appearing on that page were not incorporated into the Sequence Listing filed on that date.

Since counsel received a postcard receipt (copy enclosed) acknowledging the filing of a 293 page specification, counsel assumes that page 237 was missing only from counsel's file copy and not from the original filed with the PTO.

If counsel is mistaken, inserting page 237 at this time does not constitute the addition of "new matter". At page 1, lines 3-10, it is stated:

This application is a continuation-in-part of PCT/US99/06664, filed March 26, 1999, which is a continuation-in-part of 60/115,345, filed January 8, 1999, which is a continuation-in-part of Paige et al., Serial No. 60/099,656, filed September 9, 1998, which is a continuation-in-part of Paige et al., Serial No. 60/082,756, filed April 23, 1998. All of the above applications are hereby incorporated-by-reference.

Page 237 of this application sets forth Table 1, and part of Table 2. It is identical to page 152 of the above-identified, incorporated-by-reference PCT application. Hence, even if inadvertently omitted from this application as filed, it can be provided without adding "new matter".

In re Appln. No. 09/429,331

2. At page 162, we correct an obvious typographical error in the identification of ambiguous nucleotide "K", which denotes "G" or "T", not "C" or "T". See MPEP §2422, page 2400-20, Table 1. The NNK codon, specified at page 162, line 33, encodes all 20 amino acids. If the third position were C/T (Y), instead of G/T (K), then Met (ATG), Trp (TGG), Ser (TCA, TCG), Gln (CAA, CAG), Lys (AAA, AAG) and Gly (GAA, GAG) would not be encoded, inconsistent with the identification of X in LXXLL (page 162, line 29) as "any AA". This error was also corrected on page 4 of the Sequence Listing at <223> in SEQ ID NO:14.

3. Applicants hereby submit the following:

[XX] an amendment to the paper copy of the "Sequence Listing" submitted on February 20, 2001, the amendment being in the form of substitute pages 1 and 79 and new pages 80-90;

[XX] the Sequence Listing in computer readable form, complying with §1.821(e) and §1.824, including, if an amendment to the paper copy is submitted, all previously submitted data with the amendment incorporated therein;

[XX] 4. The description has been amended to comply with §1.821(d).

In re Appln. No. 429,331

5. The undersigned attorney or agent hereby states as follows:

- (a) this submission is not believed to include new matter [§1.821(g)];
- (b) the contents of the paper copy (as amended, if applicable) and the computer readable form of the Sequence Listing, are believed to be the same [§1.821(f) and §1.825(b)];
- (c) if the paper copy has been amended, the amendment is believed to be supported by the specification and is not believed to include new matter [§1.825(a)]; and

Respectfully submitted,

BROWDY AND NEIMARK  
Attorneys for Applicant(s)

By:

Iver P. Cooper  
Registration No. 28,005

IPC:al  
624 Ninth Street, N.W.  
Washington, D.C. 20001  
Telephone No.: (202) 628-5197  
Facsimile No.: (202) 737-3528  
F:\N\Nova\FaigalD\Pto\SequenceResponse.doc

Enclosures:

Paper Sequence Listing pp. 1,4 and 79-90  
Substitute CRF  
Substitute page 237  
Page 152 of PCT/US99/06664  
Copy of stamped postcard receipts

FILED: 28 October 1999APPLICANT(S): PAIGE et al.

THE PATENT AND TRADEMARK OFFICE STAMP HEREON  
ACKNOWLEDGES RECEIPT OF THE ABOVE-IDENTIFIED  
APPLICATION, INCLUDING THE FOLLOWING PAPERS:

☐ FEES \$ \_\_\_\_\_ (CH # \_\_\_\_\_)

☐ RULE 60 CONTINUATION, WITH:

☐ COPY OF ORIGINAL APPLICATION (\_\_\_\_\_ pages)

☐ COPY OF ORIGINAL DECLARATION

☐ COPY OF ORIGINAL DRAWINGS (if any) (\_\_\_\_\_ sheets)

☐ RULE 60 DIVISIONAL WITH:

☐ COPY OF ORIGINAL APPLICATION (\_\_\_\_\_ pages)

☐ COPY OF ORIGINAL DECLARATION

☐ COPY OF ORIGINAL DRAWINGS (if any) (\_\_\_\_\_ sheets)

☐ RULE 62 CONTINUATION

☐ (Abandon Parent)

☐ DIVISIONAL

☐ CONTINUATION-IN-PART

☐ INT'L PCT. APPLN. (\_\_\_\_\_ pages)

☐ APPT. OF AGENT ☐ FEE CALCULATION SHT.


☐ U.S. NAT'L PHASE OF INT'L APPLN. (\_\_\_\_\_ pages)

☐ OTHER \_\_\_\_\_

B&amp;N-4

DOCKET NO.: PAIGE-10 (Nom)

[PARENT CASE: \_\_\_\_\_]


☒ NEW ORIGINAL APPLICATION

☒ 293 pages

☐ CONTINUATION-IN-PART

☐ DESIGN APPLICATION

☐ PLANT PATENT APPLICATION

☒ 29 SHEETS OF DRAWINGS 21 FIG(S)

☒ TRANSMITTAL LETTER

☐ PRELIMINARY AMENDMENT(S)

☐ SMALL ENTITY STATEMENT(S)

☐ INFORMATION DISCLOSURE

☐ PRIORITY DOCUMENT(S)

☐ ASSIGNMENT

☐ DECLARATION
Initials: BCSFILED: 28 October 1999APPLICANT(S): PAIGE et al.

THE PATENT AND TRADEMARK OFFICE STAMP HEREON  
ACKNOWLEDGES RECEIPT OF THE ABOVE-IDENTIFIED  
APPLICATION, INCLUDING THE FOLLOWING PAPERS:

☐ FEES \$ \_\_\_\_\_ (CH # \_\_\_\_\_)

☐ RULE 60 CONTINUATION, WITH:

☐ COPY OF ORIGINAL APPLICATION (\_\_\_\_\_ pages)

☐ COPY OF ORIGINAL DECLARATION

☐ COPY OF ORIGINAL DRAWINGS (if any) (\_\_\_\_\_ sheets)

☐ RULE 60 DIVISIONAL WITH:

☐ COPY OF ORIGINAL APPLICATION (\_\_\_\_\_ pages)

☐ COPY OF ORIGINAL DECLARATION

☐ COPY OF ORIGINAL DRAWINGS (if any) (\_\_\_\_\_ sheets)

☐ RULE 62 CONTINUATION

☐ (Abandon Parent)

☐ DIVISIONAL

☐ CONTINUATION-IN-PART

☐ INT'L PCT. APPLN. (\_\_\_\_\_ pages)

☐ APPT. OF AGENT ☐ FEE CALCULATION SHT.


☐ U.S. NAT'L PHASE OF INT'L APPLN. (\_\_\_\_\_ pages)

☐ OTHER \_\_\_\_\_

B&amp;N-4

DOCKET NO.: PAIGE-10 (Nom)

[PARENT CASE: \_\_\_\_\_]


☒ NEW ORIGINAL APPLICATION

☒ 293 pages

☐ CONTINUATION-IN-PART

☐ DESIGN APPLICATION

☐ PLANT PATENT APPLICATION

☒ 29 SHEETS OF DRAWINGS 21 FIG(S)

☒ TRANSMITTAL LETTER

☐ PRELIMINARY AMENDMENT

☐ SMALL ENTITY STATEMENT(S)

☐ INFORMATION DISCLOSURE

☐ PRIORITY DOCUMENT(S)

☐ ASSIGNMENT

☐ DECLARATION
Initials: BCS ✓

WO 99/54728

152

PCT/US99/06664

Table 1

Peptides the Bind to the Unliganded (unactivated)  
Estrogen Receptor

|    | Sequence                      | Phage # |
|----|-------------------------------|---------|
| 5  | S R W E S P L G T W E W S R   | 4       |
|    | S A A P R T I S H Y L M G G   | 48      |
|    | S S W V R L S D F P W G V S R | 1       |
|    | S S W D R L S D F P W G V S R | 2       |
|    | S S W I R L R D L P W G E S R | 3       |
| 10 | S S W V L L R D L P W G S R   | 31      |
|    | S S W V V L R D L P W G S R   | 29      |
|    | S S C K W Y E K C S G L W S R | 7       |
|    | S S G I C F F W D G C F E S R | 35      |
|    | S R N L C F F W D D E Y C S R | 41      |
| 15 | H H H R H P A H P H T Y G G   | 47      |

Table 2

Peptides that Bind to the Estradiol Activated  
Receptor

|    | Sequence                        | Phage # |
|----|---------------------------------|---------|
| 20 | S R A G L L S D L L E G K S R   | 1/2     |
|    | S S R S L L R D L L M V D S R   | 6       |
|    | S S N K L L Y N L L K M E S R   | 22      |
|    | S S K S L L L N L L S T P S R   | 23      |
|    | H S F P R E S L L V R L L Q G G | 42      |
| 25 | S R L E M L L R S E T D F S R   | 3       |
|    | S R L E E L L K W G S V T S R   | 11      |
|    | S R L E Q L L K E E F S Y S R   | 21      |
|    | S R L E Q L L R S E P D F S R   | 27      |
|    | S R L E D L L R A P F T T S R   | 28      |
| 30 | S R L E S L L R F G Q L D S R   | 29      |
|    | S S R L L S L L V G D F N S R   | 19/20   |
|    | S R L E E L L L G T N R D S R   | 30      |
|    | S R L K E L L L L P T D L S R   | 15      |
|    | S R L E C L L E G R L N C S R   | 34      |
| 35 | S S K L Y C L L D E S Y C S R   | 35      |
|    | S R L S C L L M G F E D C S R   | 36      |
|    | S S K L I R L L T S D E E L S R | 37      |
|    | S S R L M E L L Q E G Q G W S R | 40      |
|    | S S N H Q S S R L I E L L S R   | 4       |
| 40 | S S R L W Q L L A S T D T S R   | 16      |
|    | S S N S M L W K L L A A P S R   | 13/14   |
|    | S S K T L W R L L E G E R S R   | 17      |
|    | S R A G P V L W G L L S E S R   | 32      |
|    | S S L T S R D F G S W Y A S R   | 5       |
| 45 | S S W V R L S D F P W G V S R   | 24/25   |
|    | S S E Y C F Y D S A H C S R     | 33      |
|    | S R S L L E C H L M G N C S R   | 7       |
|    | S S E L L R W H L T R D T S R   | 8       |
|    | S R L E Y W L K W E P G P S R   | 12      |
| 50 | S R S D S I L W R M L S E S R   | 31      |
|    | S S K G V L W R M L A E P V S R | 38/39   |
|    | H S H G P L T L N L L R S S G G | 41      |
|    | S S A G G G A P A G S T P S R   | 26      |

237

Table 1

Peptides the Bind to the Unliganded (unactivated)  
Estrogen Receptor

|    | Sequence                      | SEQ ID NO. | Phage # |
|----|-------------------------------|------------|---------|
| 5  | S R W E S P L G T W E W S R   | 316        | 4       |
|    | S A A P R T I S H Y L M G G   | 317        | 48      |
|    | S S W V R L S D F P W G V S R | 318        | 1       |
|    | S S W D R L S D F P W G V S R | 319        | 2       |
|    | S S W I R L R D L P W G E S R | 320        | 3       |
| 10 | S S W V L L R D L P W G S R   | 321        | 31      |
|    | S S W V V L R D L P W G S R   | 322        | 29      |
|    | S S C K W Y E K C S G L W S R | 323        | 7       |
|    | S S G I C F F W D G C F E S R | 324        | 35      |
|    | S R N L C F F W D D E Y C S R | 325        | 41      |
| 15 | H H H R H P A H P H T Y G G   | 326        | 47      |

Table 2

Peptides that Bind to the Estradiol Activated  
Receptor

|    | Sequence                        | SEQ ID NO. | Phage # |
|----|---------------------------------|------------|---------|
| 20 | S R A G L L S D L L E G K S R   | 327        | 1/2     |
|    | S S R S L L R D L L M V D S R   | 328        | 6       |
|    | S S N K L L Y N L L K M E S R   | 329        | 22      |
|    | S S K S L L L N L L S T P S R   | 330        | 23      |
|    | H S F P R E S L L V R L L Q G G | 331        | 42      |
| 25 | S R L E M L L R S E T D F S R   | 332        | 3       |
|    | S R L E E L L K W G S V T S R   | 333        | 11      |
|    | S R L E Q L L K E E F S Y S R   | 334        | 21      |
|    | S R L E Q L L R S E P D F S R   | 335        | 27      |
|    | S R L E D L L R A P F T T S R   | 336        | 28      |
| 30 | S R L E S L L R F G Q L D S R   | 337        | 29      |
|    | S S R L L S L L V G D F N S R   | 338        | 19/20   |
|    | S R L E E L L L G T N R D S R   | 339        | 30      |
|    | S R L K E L L L L P T D L S R   | 340        | 15      |
|    | S R L E C L L E G R L N C S R   | 341        | 34      |
| 35 | S S K L Y C L L D E S Y C S R   | 342        | 35      |
|    | S R L S C L L M G F E D C S R   | 343        | 36      |
|    | S S K L I R L L T S D E E L S R | 344        | 37      |
|    | S S R L M E L L Q E G Q G W S R | 345        | 40      |
|    | S S N H Q S S R L I E L L S R   | 346        | 4       |
| 40 | S S R L W Q L L A S T D T S R   | 347        | 16      |
|    | S S N S M L W K L L A A P S R   | 348        | 13/14   |
|    | S S K T L W R L L E G E R S R   | 349        | 17      |
|    | S R A G P V L W G L L S E S R   | 350        | 32      |
|    | S S L T S R D F G S W Y A S R   | 351        | 5       |
| 45 | S S W V R L S D F P W G V S R   | 352        | 24/25   |
|    | S S E Y C F Y D S A H C S R     | 353        | 33      |
|    | S R S L L E C H L M G N C S R   | 354        | 7       |
|    | S S E L L R W H L T R D T S R   | 355        | 8       |
|    | S R L E Y W L K W E P G P S R   | 356        | 12      |
| 50 | S R S D S I L W R M L S E S R   | 357        | 31      |
|    | S S K G V L W R M L A E P V S R | 358        | 38/39   |
|    | H S H G P L T L N L L R S S G G | 359        | 41      |
|    | S S A G G G A P A G S T P S R   | 360        | 26      |

## SEQUENCE LISTING

<110> PAIGE, Lisa A.  
MCDONNELL, Donald P.  
CHANG, Ching Yu  
NORRIS, John  
HAMILTON, Paul T.  
FOWLKES, Dana M.  
BARNETT, Tom  
CHRISTIANSEN, Dale J.  
BUEHRER, Benjamin

<120> METHOD OF PREDICTING THE ABILITY OF COMPOUNDS TO  
MODULATE THE BIOLOGICAL ACTIVITY OF RECEPTORS

<130> PAIGELD

<140> 09/429,331  
<141> 1999-10-28

<150> PCT/US99/06664  
<151> 1999-03-26

<150> 60/082,756  
<151> 1998-04-23

<150> 60/099,656  
<151> 1998-09-09

<150> 60/115,345  
<151> 1999-01-08

<160> 360

<170> PatentIn Ver. 2.0

<210> 1  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 1  
Ser Ser Asn His Gln Ser Ser Arg Leu Ile Glu Leu Leu Ser Arg Ser  
1 5 10 15

Gly Ser Gly Lys  
20

<210> 2  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<400> 11

Ser Ser Trp Asp Met His Gln Phe Phe Trp Glu Gly Val Ser Arg  
1 5 10 15

<210> 12

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 12

Ser Ser Pro Gly Ser Arg Glu Trp Phe Lys Asp Met Leu Ser Arg  
1 5 10 15

<210> 13

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 13

Ser Ser Leu Thr Ser Arg Asp Phe Gly Ser Trp Tyr Ala Ser Arg  
1 5 10 15

<210> 14

<211> 88

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:DNA encoding random  
peptide library of Ex. 101.1

<220>

<223> N at each occurrence is A, C, G or T; K at each  
occurrence is G or T

<400> 14

agtgtgtgcc tegagannkn nknnknnknn knnnknnkctg nnknnkctgc tgnnknnknn 60  
knnknnknnk nnktotagac tgtgcagt 88

<210> 15

<211> 15

<212> DNA

<213> Artificial Sequence



<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 313  
Ser Ser His Trp Ser Ser Asp Ser Ile Phe Pro Gly Phe Trp Tyr Ser  
1 5 10 15

Gly

<210> 314  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 314  
Ser Arg Gly Gly Val Asp Leu Asp Ile Gly Asn Ser Ala  
1 5 10

<210> 315  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 315  
Glu Gly Glu Asp Val Arg Thr Arg Ile Ala Asn  
1 5 10

<210> 316  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 316  
Ser Arg Trp Glu Ser Pro Leu Gly Thr Trp Glu Trp Ser Arg  
1 5 10

<210> 317  
<211> 14

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 317  
Ser Ala Ala Pro Arg Thr Ile Ser His Tyr Leu Met Gly Gly  
1 5 10

<210> 318  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 318  
Ser Ser Trp Val Arg Leu Ser Asp Phe Pro Trp Gly Val Ser Arg  
1 5 10 15

<210> 319  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 319  
Ser Ser Trp Asp Arg Leu Ser Asp Phe Pro Trp Gly Val Ser Arg  
1 5 10 15

<210> 320  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 320  
Ser Ser Trp Ile Arg Leu Arg Asp Leu Pro Trp Gly Glu Ser Arg  
1 5 10 15

<210> 321  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 321  
Ser Ser Trp Val Leu Leu Arg Asp Leu Pro Trp Gly Ser Arg  
1 5 10

<210> 322  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 322  
Ser Ser Trp Val Val Leu Arg Asp Leu Pro Trp Gly Ser Arg  
1 5 10

<210> 323  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 323  
Ser Ser Cys Lys Trp Tyr Glu Lys Cys Ser Gly Leu Trp Ser Arg  
1 5 10 15

<210> 324  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 324  
Ser Ser Gly Ile Cys Phe Phe Trp Asp Gly Cys Phe Glu Ser Arg  
1 5 10 15

<210> 325  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 325

Ser Arg Asn Leu Cys Phe Phe Trp Asp Asp Glu Tyr Cys Ser Arg  
1 5 10 15

<210> 326

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 326

His His His Arg His Pro Ala His Pro His Thr Tyr Gly Gly  
1 5 10

<210> 327

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 327

Ser Arg Ala Gly Leu Leu Ser Asp Leu Leu Glu Gly Lys Ser Arg  
1 5 10 15

<210> 328

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 328

Ser Ser Arg Ser Leu Leu Arg Asp Leu Leu Met Val Asp Ser Arg  
1 5 10 15

<210> 329

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Arbitrary  
peptide

&lt;400&gt; 329

Ser Ser Asn Lys Leu Leu Tyr Asn Leu Leu Lys Met Glu Ser Arg  
1 5 10 15

&lt;210&gt; 330

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Arbitrary  
peptide

&lt;400&gt; 330

Ser Ser Lys Ser Leu Leu Leu Asn Leu Leu Ser Thr Pro Ser Arg  
1 5 10 15

&lt;210&gt; 331

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Arbitrary  
peptide

&lt;400&gt; 331

His Ser Phe Pro Arg Glu Ser Leu Leu Val Arg Leu Leu Gln Gly Gly  
1 5 10 15

&lt;210&gt; 332

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Arbitrary  
peptide

&lt;400&gt; 332

Ser Arg Leu Glu Met Leu Leu Arg Ser Glu Thr Asp Phe Ser Arg  
1 5 10 15

&lt;210&gt; 333

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Arbitrary  
peptide

&lt;400&gt; 333

Ser Arg Leu Glu Glu Leu Leu Lys Trp Gly Ser Val Thr Ser Arg  
1 5 10 15

<210> 334

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 334

Ser Arg Leu Glu Gln Leu Leu Lys Glu Glu Phe Ser Tyr Ser Arg  
1 5 10 15

<210> 335

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 335

Ser Arg Leu Glu Gln Leu Leu Arg Ser Glu Pro Asp Phe Ser Arg  
1 5 10 15

<210> 336

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 336

Ser Arg Leu Glu Asp Leu Leu Arg Ala Pro Phe Thr Thr Ser Arg  
1 5 10 15

<210> 337

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 337

Ser Arg Leu Glu Ser Leu Leu Arg Phe Gly Gln Leu Asp Ser Arg  
1 5 10 15

<210> 338  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 338  
Ser Ser Arg Leu Leu Ser Leu Leu Val Gly Asp Phe Asn Ser Arg  
1 5 10 15

<210> 339  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 339  
Ser Arg Leu Glu Glu Leu Leu Leu Gly Thr Asn Arg Asp Ser Arg  
1 5 10 15

<210> 340  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 340  
Ser Arg Leu Lys Glu Leu Leu Leu Leu Pro Thr Asp Leu Ser Arg  
1 5 10 15

<210> 341  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 341  
Ser Arg Leu Glu Cys Leu Leu Glu Gly Arg Leu Asn Cys Ser Arg  
1 5 10 15

<210> 342  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 342  
Ser Ser Lys Leu Tyr Cys Leu Leu Asp Glu Ser Tyr Cys Ser Arg  
1 5 10 15

<210> 343  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 343  
Ser Arg Leu Ser Cys Leu Leu Met Gly Phe Glu Asp Cys Ser Arg  
1 5 10 15

<210> 344  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 344  
Ser Ser Lys Leu Ile Arg Leu Leu Thr Ser Asp Glu Glu Leu Ser Arg  
1 5 10 15

<210> 345  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 345  
Ser Ser Arg Leu Met Glu Leu Leu Gln Glu Gly Gln Gly Trp Ser Arg  
1 5 10 15

<210> 346  
<211> 15



<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 346  
Ser Ser Asn His Gln Ser Ser Arg Leu Ile Glu Leu Leu Ser Arg  
1 5 10 15

<210> 347  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 347  
Ser Ser Arg Leu Trp Gln Leu Leu Ala Ser Thr Asp Thr Ser Arg  
1 5 10 15

<210> 348  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 348  
Ser Ser Asn Ser Met Leu Trp Lys Leu Leu Ala Ala Pro Ser Arg  
1 5 10 15

<210> 349  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 349  
Ser Ser Lys Thr Leu Trp Arg Leu Leu Glu Gly Glu Arg Ser Arg  
1 5 10 15

<210> 350  
<211> 15  
<212> PRT  
<213> Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Arbitrary  
peptide

&lt;400&gt; 350

Ser Arg Ala Gly Pro Val Leu Trp Gly Leu Leu Ser Glu Ser Arg  
1 5 10 15

&lt;210&gt; 351

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Arbitrary  
peptide

&lt;400&gt; 351

Ser Ser Leu Thr Ser Arg Asp Phe Gly Ser Trp Tyr Ala Ser Arg  
1 5 10 15

&lt;210&gt; 352

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Arbitrary  
peptide

&lt;400&gt; 352

Ser Ser Trp Val Arg Leu Ser Asp Phe Pro Trp Gly Val Ser Arg  
1 5 10 15

&lt;210&gt; 353

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Arbitrary  
peptide

&lt;400&gt; 353

Ser Ser Glu Tyr Cys Phe Tyr Asp Ser Ala His Cys Ser Arg  
1 5 10

&lt;210&gt; 354

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 354

Ser Arg Ser Leu Leu Glu Cys His Leu Met Gly Asn Cys Ser Arg  
1 5 10 15

<210> 355

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 355

Ser Ser Glu Leu Leu Arg Trp His Leu Thr Arg Asp Thr Ser Arg  
1 5 10 15

<210> 356

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 356

Ser Arg Leu Glu Tyr Trp Leu Lys Trp Glu Pro Gly Pro Ser Arg  
1 5 10 15

<210> 357

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Arbitrary  
peptide

<400> 357

Ser Arg Ser Asp Ser Ile Leu Trp Arg Met Leu Ser Glu Ser Arg  
1 5 10 15

<210> 358

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Arbitrary  
peptide

&lt;400&gt; 358

Ser Ser Lys Gly Val Leu Trp Arg Met Leu Ala Glu Pro Val Ser Arg  
1 5 10 15

&lt;210&gt; 359

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Arbitrary  
peptide

&lt;400&gt; 359

His Ser His Gly Pro Leu Thr Leu Asn Leu Leu Arg Ser Ser Gly Gly  
1 5 10 15

&lt;210&gt; 360

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Arbitrary  
peptide

&lt;400&gt; 360

Ser Ser Ala Gly Gly Gly Ala Pro Ala Gly Ser Thr Pro Ser Arg  
1 5 10 15